FINASTERIDE AND TADALAFIL Drug Patent Profile
✉ Email this page to a colleague
When do Finasteride And Tadalafil patents expire, and when can generic versions of Finasteride And Tadalafil launch?
Finasteride And Tadalafil is a drug marketed by Zydus and is included in one NDA.
The generic ingredient in FINASTERIDE AND TADALAFIL is finasteride; tadalafil. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the finasteride; tadalafil profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Finasteride And Tadalafil
A generic version of FINASTERIDE AND TADALAFIL was approved as finasteride; tadalafil by ZYDUS on March 15th, 2024.
Summary for FINASTERIDE AND TADALAFIL
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Clinical Trials: | 2 |
Formulation / Manufacturing: | see details |
DailyMed Link: | FINASTERIDE AND TADALAFIL at DailyMed |
Recent Clinical Trials for FINASTERIDE AND TADALAFIL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Vanderbilt University Medical Center | Phase 2 |
Eli Lilly and Company | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for FINASTERIDE AND TADALAFIL
US Patents and Regulatory Information for FINASTERIDE AND TADALAFIL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Zydus | FINASTERIDE AND TADALAFIL | finasteride; tadalafil | CAPSULE;ORAL | 218232-001 | Mar 15, 2024 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |